Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Liver Transplantation | 17 | 2020 | 2864 | 2.18 | Why? |
| Liver Diseases | 6 | 2021 | 2698 | 1.33 | Why? |
| Liver Failure, Acute | 2 | 2019 | 279 | 1.10 | Why? |
| Niemann-Pick Diseases | 1 | 2019 | 3 | 0.83 | Why? |
| Lysosomal Storage Diseases | 1 | 2019 | 30 | 0.79 | Why? |
| Bile Ducts | 1 | 2018 | 84 | 0.72 | Why? |
| Intestinal Diseases | 2 | 2018 | 231 | 0.71 | Why? |
| Cholestasis | 1 | 2019 | 114 | 0.71 | Why? |
| Esophageal and Gastric Varices | 1 | 2019 | 117 | 0.67 | Why? |
| Myelitis, Transverse | 1 | 2020 | 218 | 0.67 | Why? |
| Ascites | 1 | 2017 | 65 | 0.67 | Why? |
| Facial Paralysis | 1 | 2020 | 231 | 0.65 | Why? |
| Portal Vein | 1 | 2019 | 193 | 0.64 | Why? |
| Parenteral Nutrition | 1 | 2018 | 184 | 0.64 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3633 | 0.63 | Why? |
| Transplantation Conditioning | 1 | 2018 | 323 | 0.62 | Why? |
| Down Syndrome | 1 | 2020 | 397 | 0.61 | Why? |
| Whole Exome Sequencing | 1 | 2018 | 437 | 0.59 | Why? |
| Inflammatory Bowel Diseases | 3 | 2020 | 3209 | 0.55 | Why? |
| End Stage Liver Disease | 1 | 2019 | 418 | 0.54 | Why? |
| Bilirubin | 1 | 2017 | 503 | 0.53 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2019 | 669 | 0.48 | Why? |
| Gastroenterology | 3 | 2019 | 1352 | 0.42 | Why? |
| Hepatolenticular Degeneration | 3 | 2021 | 62 | 0.41 | Why? |
| Child | 26 | 2021 | 70012 | 0.41 | Why? |
| Child, Preschool | 18 | 2020 | 36283 | 0.39 | Why? |
| Hospitals, Pediatric | 1 | 2020 | 1792 | 0.38 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.35 | Why? |
| Immunosuppressive Agents | 5 | 2020 | 6331 | 0.35 | Why? |
| Italy | 15 | 2021 | 38444 | 0.35 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.34 | Why? |
| Delayed-Action Preparations | 2 | 2019 | 291 | 0.33 | Why? |
| Pediatrics | 3 | 2019 | 2969 | 0.31 | Why? |
| Tacrolimus | 2 | 2019 | 435 | 0.31 | Why? |
| Transplant Recipients | 3 | 2020 | 4982 | 0.29 | Why? |
| Genetic Testing | 2 | 2019 | 395 | 0.29 | Why? |
| Infant | 10 | 2020 | 30274 | 0.28 | Why? |
| Hepatitis C, Chronic | 3 | 2019 | 973 | 0.28 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.27 | Why? |
| Alagille Syndrome | 2 | 2021 | 14 | 0.26 | Why? |
| Venous Thrombosis | 1 | 2019 | 2739 | 0.26 | Why? |
| Biliary Atresia | 2 | 2021 | 45 | 0.25 | Why? |
| Epidemics | 2 | 2021 | 6407 | 0.25 | Why? |
| Infant, Newborn | 7 | 2020 | 23105 | 0.23 | Why? |
| Heart Septal Defects | 1 | 2020 | 40 | 0.22 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.22 | Why? |
| Graft Survival | 3 | 2019 | 587 | 0.22 | Why? |
| Facial Nerve | 1 | 2020 | 83 | 0.22 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.21 | Why? |
| Hypersplenism | 1 | 2019 | 1 | 0.20 | Why? |
| Uridine Monophosphate | 1 | 2019 | 41 | 0.20 | Why? |
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 16 | 0.20 | Why? |
| Twins, Conjoined | 1 | 2018 | 4 | 0.20 | Why? |
| Splenomegaly | 1 | 2019 | 43 | 0.20 | Why? |
| Cholestasis, Intrahepatic | 1 | 2019 | 28 | 0.20 | Why? |
| Adolescent | 17 | 2020 | 86841 | 0.19 | Why? |
| Postoperative Complications | 2 | 2017 | 5861 | 0.19 | Why? |
| Metabolism, Inborn Errors | 1 | 2019 | 51 | 0.19 | Why? |
| Fluorenes | 1 | 2019 | 101 | 0.19 | Why? |
| Phenotype | 3 | 2019 | 4037 | 0.19 | Why? |
| Heart Transplantation | 2 | 2019 | 1293 | 0.18 | Why? |
| Hepatic Encephalopathy | 1 | 2019 | 88 | 0.18 | Why? |
| Hepatic Artery | 1 | 2018 | 31 | 0.18 | Why? |
| Wolman Disease | 1 | 2017 | 3 | 0.18 | Why? |
| Sterol Esterase | 1 | 2017 | 4 | 0.18 | Why? |
| Aneurysm, Infected | 1 | 2018 | 36 | 0.18 | Why? |
| Hypertension, Portal | 1 | 2019 | 73 | 0.18 | Why? |
| Thyroiditis, Autoimmune | 1 | 2018 | 86 | 0.18 | Why? |
| Exome | 1 | 2019 | 207 | 0.18 | Why? |
| alpha 1-Antitrypsin Deficiency | 1 | 2019 | 94 | 0.17 | Why? |
| Adrenal Hyperplasia, Congenital | 1 | 2017 | 24 | 0.17 | Why? |
| Transglutaminases | 1 | 2018 | 77 | 0.17 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.17 | Why? |
| Veins | 1 | 2018 | 168 | 0.17 | Why? |
| Monitoring, Immunologic | 1 | 2018 | 153 | 0.17 | Why? |
| Primary Graft Dysfunction | 1 | 2017 | 44 | 0.17 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.17 | Why? |
| Health Status | 2 | 2021 | 3259 | 0.16 | Why? |
| Benzimidazoles | 1 | 2019 | 275 | 0.16 | Why? |
| Catheterization | 1 | 2019 | 264 | 0.16 | Why? |
| Genetic Markers | 1 | 2018 | 318 | 0.16 | Why? |
| Humans | 39 | 2021 | 930598 | 0.16 | Why? |
| Oxidoreductases | 1 | 2017 | 136 | 0.16 | Why? |
| Arteries | 1 | 2018 | 283 | 0.16 | Why? |
| Acetaminophen | 1 | 2019 | 326 | 0.15 | Why? |
| Lysosomes | 1 | 2019 | 416 | 0.15 | Why? |
| Chagas Disease | 1 | 2018 | 155 | 0.15 | Why? |
| Hypothyroidism | 1 | 2018 | 239 | 0.15 | Why? |
| Female | 25 | 2021 | 380317 | 0.15 | Why? |
| Liver Failure | 1 | 2019 | 266 | 0.15 | Why? |
| International Normalized Ratio | 1 | 2017 | 300 | 0.15 | Why? |
| Pediatric Obesity | 1 | 2020 | 492 | 0.14 | Why? |
| Tertiary Healthcare | 1 | 2019 | 616 | 0.14 | Why? |
| Infant, Newborn, Diseases | 1 | 2019 | 394 | 0.14 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.14 | Why? |
| Hepatitis, Autoimmune | 1 | 2019 | 254 | 0.14 | Why? |
| Age Factors | 4 | 2020 | 21039 | 0.14 | Why? |
| Male | 22 | 2021 | 367725 | 0.13 | Why? |
| Community Participation | 1 | 2021 | 605 | 0.13 | Why? |
| Risk Factors | 7 | 2020 | 71621 | 0.13 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.13 | Why? |
| Infant, Premature | 1 | 2019 | 883 | 0.13 | Why? |
| Drainage | 1 | 2017 | 414 | 0.13 | Why? |
| Polyethylene Glycols | 1 | 2018 | 574 | 0.13 | Why? |
| Sleep Apnea, Obstructive | 1 | 2020 | 668 | 0.12 | Why? |
| Kaplan-Meier Estimate | 2 | 2019 | 4260 | 0.12 | Why? |
| Mass Media | 1 | 2021 | 837 | 0.12 | Why? |
| Celiac Disease | 1 | 2018 | 471 | 0.11 | Why? |
| Tissue and Organ Procurement | 2 | 2019 | 1277 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Ribavirin | 1 | 2018 | 1182 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Tertiary Care Centers | 2 | 2020 | 8248 | 0.11 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.10 | Why? |
| Autoantibodies | 2 | 2018 | 2094 | 0.10 | Why? |
| Interferon-alpha | 1 | 2018 | 1442 | 0.10 | Why? |
| Health Communication | 1 | 2021 | 1120 | 0.10 | Why? |
| Liver | 3 | 2018 | 4007 | 0.10 | Why? |
| Biopsy | 4 | 2019 | 2811 | 0.09 | Why? |
| Kidney Transplantation | 2 | 2019 | 5397 | 0.09 | Why? |
| Treatment Outcome | 7 | 2019 | 51732 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Graft Rejection | 4 | 2019 | 1766 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Drug Administration Schedule | 3 | 2019 | 2324 | 0.08 | Why? |
| Immunoglobulin A | 1 | 2018 | 3567 | 0.08 | Why? |
| Cross-Over Studies | 2 | 2019 | 867 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.08 | Why? |
| Allografts | 2 | 2019 | 761 | 0.07 | Why? |
| Retrospective Studies | 6 | 2020 | 105322 | 0.07 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.07 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Feces | 1 | 2019 | 4235 | 0.07 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.07 | Why? |
| DNA Mutational Analysis | 2 | 2018 | 581 | 0.07 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.06 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.06 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.06 | Why? |
| Situs Inversus | 1 | 2021 | 14 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Limb Deformities, Congenital | 1 | 2021 | 35 | 0.05 | Why? |
| Area Under Curve | 2 | 2019 | 2564 | 0.05 | Why? |
| Ectodermal Dysplasia | 1 | 2021 | 39 | 0.05 | Why? |
| Liver Function Tests | 2 | 2018 | 1325 | 0.05 | Why? |
| Europe | 4 | 2019 | 12702 | 0.05 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.05 | Why? |
| Scalp Dermatoses | 1 | 2021 | 59 | 0.05 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.05 | Why? |
| Umbilicus | 1 | 2018 | 12 | 0.05 | Why? |
| Biliary Tract | 1 | 2018 | 21 | 0.05 | Why? |
| Angiogenic Proteins | 1 | 2018 | 14 | 0.05 | Why? |
| Ceruloplasmin | 1 | 2018 | 12 | 0.05 | Why? |
| Health Policy | 1 | 2019 | 6242 | 0.05 | Why? |
| Steroid Metabolism, Inborn Errors | 1 | 2017 | 1 | 0.04 | Why? |
| Hepatomegaly | 1 | 2017 | 34 | 0.04 | Why? |
| Adolescent Health Services | 1 | 2019 | 95 | 0.04 | Why? |
| Bolivia | 1 | 2018 | 187 | 0.04 | Why? |
| Chelating Agents | 1 | 2018 | 61 | 0.04 | Why? |
| Adult | 6 | 2020 | 244371 | 0.04 | Why? |
| Parenteral Nutrition, Home | 1 | 2017 | 68 | 0.04 | Why? |
| Enzyme Replacement Therapy | 1 | 2017 | 65 | 0.04 | Why? |
| Duodenum | 1 | 2018 | 179 | 0.04 | Why? |
| Luminescence | 1 | 2018 | 236 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Heterozygote | 1 | 2017 | 249 | 0.04 | Why? |
| Homozygote | 1 | 2017 | 230 | 0.04 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.04 | Why? |
| Thyrotropin | 1 | 2018 | 262 | 0.04 | Why? |
| Thyroxine | 1 | 2018 | 250 | 0.04 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.04 | Why? |
| Antiviral Agents | 2 | 2019 | 41703 | 0.04 | Why? |
| Age of Onset | 1 | 2017 | 557 | 0.04 | Why? |
| Hypolipidemic Agents | 1 | 2017 | 208 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.04 | Why? |
| Sofosbuvir | 1 | 2019 | 518 | 0.04 | Why? |
| Chi-Square Distribution | 1 | 2018 | 961 | 0.03 | Why? |
| Chronic Disease | 2 | 2021 | 5139 | 0.03 | Why? |
| Copper | 1 | 2018 | 288 | 0.03 | Why? |
| Hepatitis B, Chronic | 1 | 2021 | 616 | 0.03 | Why? |
| Haplotypes | 1 | 2017 | 853 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2017 | 499 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.03 | Why? |
| Middle Aged | 5 | 2020 | 270681 | 0.03 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.03 | Why? |
| Waiting Lists | 1 | 2019 | 1388 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2021 | 1810 | 0.02 | Why? |
| Aged | 3 | 2020 | 215776 | 0.02 | Why? |
| Qualitative Research | 1 | 2021 | 4337 | 0.02 | Why? |
| Data Collection | 1 | 2017 | 1769 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.02 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Patient Safety | 1 | 2019 | 4885 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Viral Load | 1 | 2019 | 15850 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
D'Antiga's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(234)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(113)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_